A Milestone Moment: FDA Approves Addyi® for Hypoactive Sexual Desire Disorder in Postmenopausal Women
December 17, 2025
Brand Name :
Mar-cidofovir
Synonyms :
cidofovir
Class :
Antiviral agents
Dosage Forms & Strengths
Suspension, Intravenous:
75 mg/ml (5ml)
Premedication (to minimize the risk of nephrotoxicity): 2g probenecid 3 hours before the cidofovir dose, then 1g 2hr and 8hr after cidofovir infusion.
5
mg/kg
Intravenous (IV)
once a week
or
1 mg/kg 3 times weekly with concomitant probenecid
3 - 5
mg/kg
Intravenous (IV)
every 1 to 2 weeks with concomitant probenecid
or
5 mg/kg intravesicular dose instilled into bladder once weekly
Induction dose:
5
mg/kg
Intravenous (IV)
once a week for 2 weeks
Maintenance dose: 5 mg/kg IV once every 2 weeks
Acyclovir resistance:
5
mg/kg
Intravenous (IV)
once a week for 3 weeks
For mucocutaneous infection: Apply 1% Topical gel (cidofovir) once a day for 5 days
Dose Adjustments
Dose adjustments for renal impairment:
CrCl >1.3 ml/min: 5 mg/kg
CrCl 1 to 1.2 ml/min: 4 mg/kg
CrCl 0.8 to 0.9 ml/min: 3 mg/kg
CrCl 0.7 ml/min: 2.5 mg/kg
CrCl 0.5 to 0.6 ml/min: 2 mg/kg
CrCl 0.4 ml/min: 1.5 mg/kg
CrCl 0.2 to 0.3 ml/min: 1 mg/kg
CrCl 0.1 ml/min: 0.5 mg/kg
Dosage Forms & Strengths
Suspension, Intravenous:
75 mg/ml (5ml)
Premedication (to minimize the risk of nephrotoxicity): 25 to 40 mg/kg probenecid 3 hours before the cidofovir dose, then 10 mg 2hr and 8hr after cidofovir infusion.
5
mg/kg
Intravenous (IV)
once a week
or
1 mg/kg IV 3 times weekly
0.25 - 1
mg/kg
Intravenous (IV)
every 1 to 3 weeks without probenecid
For hemorrhagic cystitis in hematopoietic cell transplant recipients:
3 to 5 mg/kg IV every 1 to 2 weeks with concomitant probenecid
both cidofovir and acyclovir exacerbate ototoxicity and/or nephrotoxicity
It may enhance the serum concentration of cabozantinib
It may decrease the therapeutic efficacy of cladribine
When cidofovir is used together with piroxicam, this leads to increased risk or seriousness of nephrotoxicity
When cefmenoxime is used together with cidofovir, this leads to enhanced risk or seriousness of nephrotoxicity
cidofovir leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
cidofovir leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
When cidofovir is used together with difenpiramide, this leads to enhanced risk or seriousness of nephrotoxicity
caffeic acid when combined with cidofovir results in more adverse effects
the severity of nephrotoxicity can be enhanced when cidofovir is administered with mufebutazone
cidofovir might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
Frequency defined:
>10%
Decreased serum bicarbonate
Proteinuria
Neutropenia
Hypotony of eye
Iritis
Uveitis
Fever
Increased serum creatinine
Nephrotoxicity
1% to 10%:
Fanconi syndrome
Nausea
Vomiting
Acute kidney injury
Post-marketing:
Pancreatitis
Hepatic insufficiency
Metabolic acidosis
Pregnancy consideration: Not recommended during the first trimester of pregnancy due to fetal outcomes.
Lactation: Cidofovir excretion in breast milk is not known. Do not use during breastfeeding considering the risk of infant exposure.
Pregnancy category:
Patient information leaflet
Generic Name: Cidofovir
Pronunciation: Ci-do-fo-vir
Why do we use Cidofovir?
It is used to treat a viral infection of the eyes in HIV-positive people. It is also used to treat other viral infections.
Cidofovir has been considered an alternative antiviral agent to treat monkeypox infection, animal studies reported evidence of teratogenicity.